Increased Investment in Pharmaceutical Manufacturing Equipment at the Joto Plant
First written in FY2018. 7 of 14 entries say "Advanced", first in FY2019. Latest entry: 2026-09-30.
0 other companies' latest entry also says "Advanced".
- 2026-09-30AdvancedTimely disclosure
「Based on this policy, we have decided to enter into a design and construction contract with CXO, which has extensive expertise in constructing pharmaceutical manufacturing plants, for the construction of 岡山第二工場, equipped with a multi-level automated warehouse, on the premises of 岡山工場, with the aim of further strengthening our BCP (business continuity plan) and improving production efficiency.」
The plan progressed to the contract stage with the execution of the design and construction contract. The company also disclosed a total investment of approximately ¥14.0 billion and a schedule of construction starting in December 2026, completion in March 2028 and the start of production in December 2028. - FY2026AdvancedAnnual report
「The Company's future capital investment plan includes constructing the Okayama No. 2 Plant on the site of the Okayama Plant as part of its efforts to achieve medium- to long-term growth. The new plant will include a five-story steel-frame formulation building with a total floor area of approximately 7,000 m² and an automated warehouse, and is scheduled to begin production by the end of 2028. The Company has decided to install a new powder dialysate production line at this plant and transfer and consolidate the functions of the Daito Plant there.」
The focus of plant investment advanced from capital investment in individual plants to a specific restructuring plan involving construction of the Okayama No. 2 Plant, installation of a new powder dialysate line, and transfer and consolidation of the Daito Plant's functions. - FY2025ReframedAnnual report
「During the current fiscal year, the Company financed investments mainly related to its ERP system and research and development activities under this policy. In the following fiscal year, the Company plans to invest mainly in pharmaceutical manufacturing equipment at each plant as capital expenditure, while promoting further development of dialysis care and research and development activities in new fields. The Company will arrange the necessary financing in accordance with this policy as needed.」
The focus of investment in the current fiscal year shifted from the new line at the Ibaraki Plant to the ERP system and research and development activities. The Company plans to invest in pharmaceutical manufacturing equipment at each plant and in research and development in the following fiscal year. - FY2024AdvancedAnnual report
「During the current fiscal year, the Company financed investments in the expansion of a new line for powder dialysate manufacturing equipment for artificial kidneys at Building 2 of the Ibaraki Plant, which began operations in January 2024, as well as research and development activities under this policy. In the following fiscal year, the Company plans to invest mainly in pharmaceutical manufacturing equipment at each plant as capital expenditure and to promote further development of dialysis care and research and development activities in new fields.」
The Company invested in a new line at Building 2 of the Ibaraki Plant and plans to invest in manufacturing equipment at each plant in the following fiscal year. - FY2023AdvancedAnnual report
「During the current fiscal year, the Company financed investments in the expansion of a new line for powder dialysate manufacturing equipment at Building 2 of the Ibaraki Plant and research and development activities under this policy. In the following fiscal year, the Company plans to continue investing in the expansion of the new line for powder dialysate manufacturing equipment at Building 2 of the Ibaraki Plant, as well as in other pharmaceutical production facilities and related equipment, while promoting further development of dialysis care and research and development activities in new fields. The Company will arrange the necessary financing in accordance with this policy as needed.」
The Company invested in expanding a new line for powder dialysate manufacturing equipment at Building 2 of the Ibaraki Plant and plans to continue this investment and invest in other pharmaceutical manufacturing equipment in the following fiscal year. - FY2022ReframedAnnual report
「During the current fiscal year, the Company financed investments mainly in the expansion of a new line for powder dialysate manufacturing equipment at Building 2 of the Ibaraki Plant and research and development activities under this policy. In the following fiscal year, the Company plans to invest mainly in pharmaceutical production facilities and manufacturing equipment as capital expenditure, while promoting further development of dialysis care and research and development activities in new fields. The Company will arrange the necessary financing in accordance with this policy as needed.」
The Company invested in the Ibaraki Plant in the current fiscal year, while broadening the scope of the following fiscal year's planned investment from a focus on a specific plant to pharmaceutical production facilities and manufacturing equipment generally. - FY2021RestatedAnnual report
「During the current fiscal year, the Company financed investments mainly in pharmaceutical manufacturing equipment at the Ibaraki Plant and research and development activities under this policy. In the following fiscal year, the Company plans to invest mainly in pharmaceutical manufacturing equipment at the Ibaraki Plant as capital expenditure and to continue research and development activities at the same level as in the current fiscal year. The Company will arrange the necessary financing in accordance with this policy.」
The Company focused capital investment in production facilities on the Ibaraki Plant, made investments in the current fiscal year, and plans to continue investing in the following fiscal year. - FY2020ReframedAnnual report
「During the current fiscal year, the Company financed investments mainly in pharmaceutical manufacturing equipment at the Ibaraki Plant and research and development activities under this policy. In the following fiscal year, the Company plans to invest mainly in pharmaceutical manufacturing equipment at the Ibaraki Plant as capital expenditure and to continue research and development activities at the same level as in the current fiscal year. The Company will arrange the necessary financing in accordance with this policy.」
The focus of capital investment in production facilities shifted from the Joto Plant to pharmaceutical manufacturing equipment at the Ibaraki Plant. The Company invested in the Ibaraki Plant in the current fiscal year and plans to continue investing there in the following fiscal year. - FY2019AdvancedAnnual report
「During the current fiscal year, the Company financed investments mainly in pharmaceutical manufacturing equipment at the Joto Plant and research and development activities under this policy. In the following fiscal year, the Company plans to invest mainly in pharmaceutical manufacturing equipment at each plant as capital expenditure and to continue research and development activities at the same level as in the current fiscal year. The Company will arrange the necessary financing in accordance with this policy.」
The Company invested in pharmaceutical manufacturing equipment at the Joto Plant and plans to invest at each plant and maintain research and development activities at the same level in the following fiscal year. - FY2018First statedAnnual report
「In the following fiscal year, the Company plans to invest more than in the current fiscal year in pharmaceutical manufacturing equipment at the Joto Plant as a major capital expenditure, while continuing research and development activities at the same level as in the current fiscal year. The Company will arrange the necessary financing in accordance with this policy.」
The Company plans to invest more than in the current fiscal year in pharmaceutical manufacturing equipment at the Joto Plant in the following fiscal year.